Sulfadiazine

Research use only, not for human use.

Sulfadiazine is a sulfonamide antibiotic. It eliminates bacteria that cause infections by stopping the production of folic acid inside the bacterial cell, and is commonly used to treat urinary tract infections (UTIs).

Sulfadiazine is a sulfonamide antibiotic. It eliminates bacteria that cause infections by stopping the production of folic acid inside the bacterial cell, and is commonly used to treat urinary tract infections (UTIs). In combination, sulfadiazine and pyrimethamine, can be used to treat toxoplasmosis, a disease caused by Toxoplasma gondii.(In Vitro):In this study, the effectiveness of Sulfadiazine and Pyrimetamine for the treatment of mice during acute infection with different atypical T. gondii strains was evaluated. Swiss mice were infected with seven T. gondii strainsl. The infected mice were treated with 10-640 mg/kg per day of Sulfadiazine, 3-200 mg/kg per day of Pyrimetamine, or a combination of both drugs with a lower dosage. A descriptive analysis was used to assess the association between susceptibility to Sulfadiazine and/or Pyrimetamine and the genotype. The TgCTBr4 and TgCTBr17 strains (genotype 108) presented lower susceptibility to Sulfadiazine or Pyrimetamine treatment. The TgCTBr1 and TgCTBr25 strains (genotype 206) presented similar susceptibility to PYR but not Sulfadiazine treatment. The TgCTBr9 strain (genotype 11) was the only strain with high susceptibility to treatment with both drugs.

——

In this study, the effectiveness of Sulfadiazine and Pyrimetamine for the treatment of mice during acute infection with different atypical T. gondii strains was evaluated. Swiss mice were infected with seven T. gondii strainsl. The infected mice were treated with 10-640?mg/kg per day of Sulfadiazine, 3-200?mg/kg per day of Pyrimetamine, or a combination of both drugs with a lower dosage. A descriptive analysis was used to assess the association between susceptibility to Sulfadiazine and/or Pyrimetamine and the genotype. The TgCTBr4 and TgCTBr17 strains (genotype 108) presented lower susceptibility to Sulfadiazine or Pyrimetamine treatment. The TgCTBr1 and TgCTBr25 strains (genotype 206) presented similar susceptibility to PYR but not Sulfadiazine treatment. The TgCTBr9 strain (genotype 11) was the only strain with high susceptibility to treatment with both drugs.

NSC 35600

Autophagy

Autophagy

DHPS

Infection

——

68-35-9

250.28

C10H10N4O2S

>98% (HPLC)

DMSO: 50 mg/mL (199.77 mM)

O=S(NC1=NC=CC=N1)(C2=CC=C(N)C=C2)=O

4-amino-N-(pyrimidin-2-yl)benzenesulfonamide

(-20℃)

With Ice Pack

≥ 2 years